Search hospitals > Hawaii > Aiea
Straub Pearlridge Clinic
Claim this profileAiea, Hawaii 96701
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Parotid Gland Cancer
Conducts research for Prostate Cancer
Conducts research for Breast Cancer
14 reported clinical trials
4 medical researchers
Summary
Straub Pearlridge Clinic is a medical facility located in Aiea, Hawaii. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Parotid Gland Cancer, Prostate Cancer, Breast Cancer and other specialties. Straub Pearlridge Clinic is involved with conducting 14 clinical trials across 146 conditions. There are 4 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Stuart Tsuji, MD, Teruo Yamauchi, and Charles O. Kim.Area of expertise
1Lung Cancer
Stage III
Stage IV
Stage I
2Non-Small Cell Lung Cancer
Stage III
Stage IV
Stage I
Top PIs
Jeffrey L. BerenbergStraub Clinic and Hospital1 year of reported clinical research
Expert in Lung Cancer
Expert in Parotid Gland Cancer
29 reported clinical trials
77 drugs studied
Stuart Tsuji, MDQueen's Medical Center7 years of reported clinical research
Studies Glioblastoma
Studies Dementia
3 reported clinical trials
4 drugs studied
Teruo YamauchiSt. Luke's International Hospital1 year of reported clinical research
Studies Breast Cancer
Studies Cognitive Impairment
2 reported clinical trials
6 drugs studied
Charles O. KimUniversity of Hawaii Cancer Center8 years of reported clinical research
Studies Prostate Cancer
Studies Prostatic Neoplasm
2 reported clinical trials
5 drugs studied
Clinical Trials running at Straub Pearlridge Clinic
Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
ALK Gene Rearrangement
Skin Cancer
Cutaneous Melanoma
Parotid Gland Cancer
Anaplastic Large Cell Lymphoma
Relapse
Cognitive Impairment
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Straub Pearlridge Clinic?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.